209 related articles for article (PubMed ID: 21221182)
1. Infliximab: the evidence for its place in therapy in ulcerative colitis.
Van Assche G; Vermeire S; Rutgeerts P
Core Evid; 2008 Feb; 2(3):151-61. PubMed ID: 21221182
[TBL] [Abstract][Full Text] [Related]
2. Tumor necrosis factor alpha blocking agents as treatment for ulcerative colitis intolerant or refractory to conventional medical therapy: a meta-analysis.
Lv R; Qiao W; Wu Z; Wang Y; Dai S; Liu Q; Zheng X
PLoS One; 2014; 9(1):e86692. PubMed ID: 24475168
[TBL] [Abstract][Full Text] [Related]
3. Tumour necrosis factor alpha blocking agents for induction of remission in ulcerative colitis.
Lawson MM; Thomas AG; Akobeng AK
Cochrane Database Syst Rev; 2006 Jul; (3):CD005112. PubMed ID: 16856078
[TBL] [Abstract][Full Text] [Related]
4. Etrolizumab versus infliximab for the treatment of moderately to severely active ulcerative colitis (GARDENIA): a randomised, double-blind, double-dummy, phase 3 study.
Danese S; Colombel JF; Lukas M; Gisbert JP; D'Haens G; Hayee B; Panaccione R; Kim HS; Reinisch W; Tyrrell H; Oh YS; Tole S; Chai A; Chamberlain-James K; Tang MT; Schreiber S;
Lancet Gastroenterol Hepatol; 2022 Feb; 7(2):118-127. PubMed ID: 34798038
[TBL] [Abstract][Full Text] [Related]
5. A review of infliximab use in ulcerative colitis.
Wilhelm SM; McKenney KA; Rivait KN; Kale-Pradhan PB
Clin Ther; 2008 Feb; 30(2):223-30. PubMed ID: 18343261
[TBL] [Abstract][Full Text] [Related]
6. Colectomy rate in acute severe ulcerative colitis in the infliximab era.
Aratari A; Papi C; Clemente V; Moretti A; Luchetti R; Koch M; Capurso L; Caprilli R
Dig Liver Dis; 2008 Oct; 40(10):821-6. PubMed ID: 18472316
[TBL] [Abstract][Full Text] [Related]
7. Infliximab for the treatment of ulcerative colitis: outcomes in Oxford from 2000 to 2006.
Jakobovits SL; Jewell DP; Travis SP
Aliment Pharmacol Ther; 2007 May; 25(9):1055-60. PubMed ID: 17439506
[TBL] [Abstract][Full Text] [Related]
8. Infliximab for the treatment of acute exacerbations of ulcerative colitis.
Bryan S; Andronis L; Hyde C; Connock M; Fry-Smith A; Wang D
Health Technol Assess; 2010 May; 14 Suppl 1():9-15. PubMed ID: 20507798
[TBL] [Abstract][Full Text] [Related]
9. Patient preferences and current practice for adults with steroid-resistant ulcerative colitis: POPSTER mixed-methods study.
Coates E; Wickramasekera N; Barr A; Shackley P; Lee M; Hind D; Probert C; Sebastian S; Totton N; Blackwell S; Bedford H; Dames N; Lobo A
Health Technol Assess; 2022 Oct; 26(41):1-118. PubMed ID: 36305390
[TBL] [Abstract][Full Text] [Related]
10. Infliximab is effective in acute but not chronic childhood ulcerative colitis.
Russell GH; Katz AJ
J Pediatr Gastroenterol Nutr; 2004 Aug; 39(2):166-70. PubMed ID: 15269622
[TBL] [Abstract][Full Text] [Related]
11. Randomised controlled trial. Comparison Of iNfliximab and ciclosporin in STeroid Resistant Ulcerative Colitis: Trial design and protocol (CONSTRUCT).
Seagrove AC; Alam MF; Alrubaiy L; Cheung WY; Clement C; Cohen D; Grey M; Hilton M; Hutchings H; Morgan J; Rapport F; Roberts SE; Russell D; Russell I; Thomas L; Thorne K; Watkins A; Williams JG
BMJ Open; 2014 Apr; 4(4):e005091. PubMed ID: 24785401
[TBL] [Abstract][Full Text] [Related]
12. Intensified Infliximab Induction is Associated with Improved Response and Decreased Colectomy in Steroid-Refractory Paediatric Ulcerative Colitis.
Church PC; Ho S; Sharma A; Tomalty D; Frost K; Muise A; Walters TD; Griffiths AM
J Crohns Colitis; 2019 Aug; 13(8):982-989. PubMed ID: 30715240
[TBL] [Abstract][Full Text] [Related]
13. The impact of biological interventions for ulcerative colitis on health-related quality of life.
LeBlanc K; Mosli MH; Parker CE; MacDonald JK
Cochrane Database Syst Rev; 2015 Sep; 2015(9):CD008655. PubMed ID: 26393522
[TBL] [Abstract][Full Text] [Related]
14. Anti-tumour necrosis factor therapy for ulcerative colitis: evidence to date.
Thukral C; Cheifetz A; Peppercorn MA
Drugs; 2006; 66(16):2059-65. PubMed ID: 17112300
[TBL] [Abstract][Full Text] [Related]
15. Infliximab in steroid-dependent ulcerative colitis: effectiveness and predictors of clinical and endoscopic remission.
Armuzzi A; Pugliese D; Danese S; Rizzo G; Felice C; Marzo M; Andrisani G; Fiorino G; Sociale O; Papa A; De Vitis I; Rapaccini GL; Guidi L
Inflamm Bowel Dis; 2013 Apr; 19(5):1065-72. PubMed ID: 23448790
[TBL] [Abstract][Full Text] [Related]
16. Infliximab and ulcerative colitis.
Cottone M; Mocciaro F; Modesto I
Expert Opin Biol Ther; 2006 Apr; 6(4):401-8. PubMed ID: 16548766
[TBL] [Abstract][Full Text] [Related]
17. Infliximab for treatment of steroid-refractory ulcerative colitis.
Actis GC; Bruno M; Pinna-Pintor M; Rossini FP; Rizzetto M
Dig Liver Dis; 2002 Sep; 34(9):631-4. PubMed ID: 12405249
[TBL] [Abstract][Full Text] [Related]
18. Cyclosporine A for induction of remission in severe ulcerative colitis.
Shibolet O; Regushevskaya E; Brezis M; Soares-Weiser K
Cochrane Database Syst Rev; 2005 Jan; (1):CD004277. PubMed ID: 15674937
[TBL] [Abstract][Full Text] [Related]
19. Long-term outcome of infliximab treatment in chronic active ulcerative colitis: a Swedish multicentre study of 250 patients.
Angelison L; Almer S; Eriksson A; Karling P; Fagerberg U; Halfvarson J; Thörn M; Björk J; Hindorf U; Löfberg R; Bajor A; Hjortswang H; Hammarlund P; Grip O; Torp J; Marsal J; Hertervig E;
Aliment Pharmacol Ther; 2017 Feb; 45(4):519-532. PubMed ID: 28025840
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of biosimilar infliximab CT-P13 among inpatients with severe steroid-refractory colitis.
Ollech JE; Normatov I; Peleg N; Dalal SR; Pekow J; Micic D; Cohen RD; Rubin DT; Sakuraba A
Int J Colorectal Dis; 2020 Nov; 35(11):2113-2116. PubMed ID: 32710391
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
